Counting on Europe
Bayer built the cell and gene therapy toolbox. Now Europe has to decide whether to pay for it.
Issue 01 · Autumn 2026 · Out now
A premium print quarterly for the people shaping the future of health and life sciences in Europe.
The Inaugural Issue
Bayer built the cell and gene therapy toolbox. Now Europe has to decide whether to pay for it.
nexxahealth reaches decision-makers, not just readers. A print-led quarterly built for the institutions, companies and individuals setting the direction of health & life sciences across Europe. Small, deliberate circulation; high-influence hands.
Commission, Parliament and Council staff working on health policy.
Decision-makers across the member states.
The people who fund, commission and run care.
From established leaders to emerging innovators.
The builders of Europe’s next models of care.
Clinicians, scientists and research institutes.
The advocates at the centre of the debate.
The capital and networks behind European health.
The voices connecting industry and policy.